CD4+ T Cells Mediate Dendritic Cell Licensing to Promote Multi‐Antigen Anti‐Leukemic Immune Response
ABSTRACT Background Single antigen (Ag)‐targeted immunotherapies for acute lymphoblastic leukemia (ALL) are highly effective; however, up to 50% of patients relapse after these treatments. Most of these relapses lack target Ag expression, suggesting targeting multiple Ags would be advantageous. Mate...
Saved in:
Main Authors: | Luis Gil‐de‐Gómez, Joseph J. Mattei, Jessica H. Lee, Stephan A. Grupp, Gregor S. D. Reid, Alix E. Seif |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-01-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.70508 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES
by: Ugo Testa, et al.
Published: (2024-02-01) -
Concentration-dependent effects of immunomodulatory cocktails on the generation of leukemia-derived dendritic cells, DCleu mediated T-cell activation and on-target/off-tumor toxicity
by: Hazal Aslan Rejeski, et al.
Published: (2025-01-01) -
T cell receptors specific for an imatinib-induced mutation in BCR-ABL for adoptive T cell therapy
by: Meng-Tung Hsu, et al.
Published: (2025-01-01) -
Editorial: Antigen presentation in cancer immune responses
by: Marie-Liesse Asselin-Labat, et al.
Published: (2025-01-01) -
CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells
by: Lucas Touzet, et al.
Published: (2019-03-01)